Fundraising FoxArix Bioscience — Full Portfolio
11 tracked investments · listed companies and verified rows first
Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.
BiotechHealthtechMedical DevicesCambridge, US
Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)
Co-investorsAdvent Life SciencesChiesi VenturesColumbus Venture PartnersDroia VenturesForesite CapitalJazzya Investments+6 more
Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.
BiotechHealthtech
John Quisel(Chief Executive Officer)inJean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)inPamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in
Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesForesite CapitalFrazier Life SciencesOrbiMed+7 more
Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion.
BiotechCambridge, US
James G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)Richard Fair(President, Chief Executive Officer, Director)
BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)
Co-investorsBay City CapitalNew Enterprise Associates (NEA)Pfizer Venture InvestmentsRA CapitalAlexandriaJMI Equity+3 more
Developing a new class of antifungal medicine to overcome limitations of current therapies.
Co-investorsBioBritGolden SeedsKeiretsu ForumPappas CapitalSofinnova Ventures3x5 Partners+4 more
Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.
BiotechHealthtechMedical Devices
Co-investorsAndera PartnersDementia Discovery FundM VenturesNovartis Venture FundPfizer Venture InvestmentsRA Capital+6 more
Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.
BiotechHealthtechMedical DevicesBoston, US
Albert Seymour(Director)
BoardKush Parmar(Executive Officer, Director)inPaula Soteropoulos(Director)Stephen Knight(Director)in
Co-investors5AM VenturesAju IB InvestmentCatalio Capital Management, LPDelos CapitalF-Prime CapitalSolasta Ventures+10 more
A research-intensive biopharmaceutical company that develops medicines and vaccines.
BiotechHealthtechSouth San Francisco, US
Luke Nathaniel Walker(Executive Officer)Julie Eastland(Executive Officer, Director)in
BoardRonald Hunt(Director)Mark Chin(Director)Alan Colowick(Director)Jonathan Drachman(Director)
Co-investorsK2 HealthVenturesRidgeback CapitalTaiho Ventures, LLCLilly Asia VenturesMPM BioImpactNew Leaf Venture Partners+1 more
LogicBio is a biotechnology company focused on research and development of treatments for rare diseases, investigating new targets, modalities, and technologies for patients and their families worldwide.
BiotechHealthtechCambridge, US
Leszek Lisowski(Executive Officer, Director)Mark A. Kay(Director)Adi Barzel(Executive Officer, Director)
BoardErez Chimovits(Director)in
Co-investorsAndera PartnersPontifax Venture CapitalSBI JI Innovation Advisory Ltd.OrbiMed
A biopharmaceutical company developing medicines and vaccines with a focus on clinical research and development for human health.
BiotechSan Diego, US
David Johnson(Executive Officer, Director)Cam Gallagher(Director)Scott L. Glenn(Director)in
Co-investorsChiesi VenturesDecheng CapitalPappas CapitalSofinnova VenturesVedanta CapitalViking Global+4 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Amplyx PharmaceuticalsAutolus
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.